AbbVie (NYSE:ABBV) is ticking up; according to a new Samsung Bioepis report, Humira's U.S. market share stays above 70% even with increasing biosimilar competition.
Losing U.S. exclusivity in early 2023, Humira, the top-selling arthritis medication from AbbVie, let biosimilars from Amgen (NASDAQ:AMGN), Teva (NYSE:TEVA), and Pfizer (NYSE:PFE) onto the market. After factoring over a third of AbbVie's income in 2022, Humira's share fell to 27% in 2023.
Humira still dominated 96% of the market as of February 2024, but its share dropped to 77% in May after several pharmacy benefit managers, notably CVS Health (CVS), kicked it off important formularies.AbbVie has 72% of the adalimumab market as of November 2024; biosimilars are taking center stage, rising from 2% to 23% in a year. Humira is still the leading market participant even with the evolving rivalry.
This article first appeared on GuruFocus.免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。